AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced topline data from the Phase 2b SOLANO study of ION449 (AZD8233) for hypercholesterolemia (high cholesterol levels).…
There’s ‘Outsized’ Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with an Overweight (previously Underweight) rating and a price target of $57 from…
Morgan Stanley Upgrades Ionis Pharmaceuticals to Overweight, Raises Price Target to $57
Morgan Stanley analyst Andrew Galler upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Underweight to Overweight and raises the price target from $30 to $57.
Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
Ionis and Astrazeneca’s Eplontersen Demonstrated a Statistically Significant and Clinically Meaningful Change From Baseline for Co-primary and Secondary Endpoints at 35 Weeks vs External Placebo Group
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $64
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $67 to $64.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.